AstraZeneca Shrugs Off COVID Antibody’s Inferiority In Therapy Setting, Sees Prevention As Main Role

Injection Cut Risk By 50%

AstraZeneca’s anti-SARS-CoV-2 antibody product is unlikely to rival Regeneron or Vir/GSK’s offerings in mild-to-moderate patients, where Merck’s newly-submitted oral molnupiravir will also change treatment.

AstraZeneca biologics
AstraZeneca's 600mg intramuscular dose is much lower than rival IV therapies, which should make hitting production easier, but the company is not disclosing its manufacturing targets.

AstraZeneca’s injectable antibody therapy AZD7442 has succeeded in cutting risk of people with COVID-19 progressing to severe illness or death, but has fallen short of the efficacy achieved in similar studies of rival treatments from Regeneron, Eli Lilly and Vir/GSK.

Results from its Phase III TACKLE study found that AZD7442 (tixagevimab and cilgavimab) given by intramuscular injection, cut the risk...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip